ClinicalTrials.gg
Status unknownNCT04105595CBSO RegistryUpdated Jul 21, 2022

Post Market Registry of the CBSO

An observational study in Atrial Septal Defect and Patent Foramen Ovale, sponsored by atHeart Medical. Status unknown at 1 site in Germany. Per ClinicalTrials.gov, last updated 2022-07-21.

Primary conditionForamen Ovale, PatentRegistry: Heart Septal Defects, AtrialReclassifiedWhy we changed it
Registry
Heart Septal Defects, Atrial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Foramen Ovale, Patent
Why
  1. The study's listed conditions name Foramen Ovale, Patent, a narrower term within Heart Septal Defects, Atrial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by atHeart Medical · Observational

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
6
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Foramen Ovale, Patent with a site in Germany — 3 open to participants now, 6 under way, none of them phase 3. Foramen Ovale, Patent · Germany.

Started
2020
with 2 others
Observational
7 of 21
2 open now
Registered
15th of 21
by date
Lead sponsor
1 of 21
atHeart Medical

Among the 21 studies in Foramen Ovale, Patent with a site in Germany, this one is one of 3 that started in 2020, is one of 7 observational ones, and was the 15th registered.

Foramen Ovale, Patent

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

Browse Foramen Ovale, Patent studies →

Open to participants now

3 of the 21 studies in Foramen Ovale, Patent with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Foramen Ovale, Patent with a site in Germany, or all of them as a file.
02

Study summary

Multi centre, international, post market registry to monitor the clinical performance and safety of an atrial septal closure device with biodegradable framework in patients with clinically significant atrial septum defect (ASD) or patent foramen ovale (PFO) in routine clinical use

03

Conditions studied

  • Atrial Septal Defect
  • Patent Foramen Ovale

Browse trials for

04

In context

Foramen Ovale, Patent Reclassified

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

This study's enrollment of 6 is below the median of 252 across 60 observational studies indexed under Foramen Ovale, Patent.

Browse Foramen Ovale, Patent studies →

Lead sponsor

atHeart Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Foramen Ovale, Patent, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Septal Defects, Atrial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Intent to treat population: All enrolled patients Modified Intent to Treat population: All enrolled patients who have a permanently implanted CBSO.

Per Protocol population: All patients in the enrolled population who have a permanently implanted CBSO and do not have a major protocol deviation. The per protocol population will be used as the final population for analysis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient suffers from ASD (including ostium secundum ASD or a fenestration from a Fontan procedure) or PFO and is planned to receive the CBSO.
  • Patient (or legal guardian) has been informed and agreed to and signed the form.
  • A CBSO is implanted into the patient.

Exclusion criteria

Exclusion Criteria:

  • Patient is known to have one or more of the listed in the instructions for use.
  • Patient is currently participating in one or more interventional studies, with exception of a study investigating the CBSO.
  • Patient is implanted with another product in the atrial septum.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
6 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • ASD patients

    Device: Septal defect closure

  • PFO patients

    Device: Septal defect closure

Interventions

  • DeviceSeptal defect closure

    Device closure of atrial septal defect

07

What researchers measure

Primary outcomes

  1. Effective closure by echocardiography

    Time frame: at 6 months

  2. Safety throughout the follow up duration by absence of serious incidents

    Time frame: day 0 to 3 years

08

Study locations

1 site
  • Deutsches Herzzentrum Berlin
    Berlin, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Oct 2023, 43 months after the start.

Of 29 observational studies under Foramen Ovale, Patent, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 92. This study's planned 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2019
First posted
Sep 26, 2019
StartActual
Mar 5, 2020
Primary completionEst.
Oct 2023
CompletionEst.
Oct 2024
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04105595
Lead sponsor
atHeart Medical
Responsible party
Sponsor
First posted
Sep 26, 2019
Start date
Mar 5, 2020
Primary completion
Oct 2023 (estimated)
Completion
Oct 2024 (estimated)
Last update
Jul 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion